William H. Koster

eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA.

Ocuterra Therapeutics, Inc. manufactures drug products. The company is headquartered in Boston, MA.

Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc.

Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT.

Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA.

Phytomedics, Inc. discovers, develops, and manufactures botanical therapeutics using proprietary platform technologies. The company was founded in December 1996 by Ilya Raskin and is headquartered in Jamesburg, NJ.

Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.